- Home
- QNCX vs STTK Comparison
QNCX vs STTK Comparison
Compare QNCX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- STTK
- Stock Information
- Founded
- QNCX 2012
- STTK 2016
- Country
- QNCX United States
- STTK United States
- Employees
- QNCX N/A
- STTK N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- QNCX Health Care
- STTK Health Care
- Exchange
- QNCX Nasdaq
- STTK Nasdaq
- Market Cap
- QNCX 47.7M
- STTK 38.4M
- IPO Year
- QNCX 2019
- STTK 2020
- Fundamental
- Price
- QNCX $1.68
- STTK $0.84
- Analyst Decision
- QNCX Strong Buy
- STTK Hold
- Analyst Count
- QNCX 5
- STTK 4
- Target Price
- QNCX $8.00
- STTK $3.00
- AVG Volume (30 Days)
- QNCX 235.8K
- STTK 228.4K
- Earning Date
- QNCX 08-12-2025
- STTK 08-04-2025
- Dividend Yield
- QNCX N/A
- STTK N/A
- EPS Growth
- QNCX N/A
- STTK N/A
- EPS
- QNCX N/A
- STTK N/A
- Revenue
- QNCX N/A
- STTK $4,606,000.00
- Revenue This Year
- QNCX N/A
- STTK N/A
- Revenue Next Year
- QNCX N/A
- STTK N/A
- P/E Ratio
- QNCX N/A
- STTK N/A
- Revenue Growth
- QNCX N/A
- STTK 69.65
- 52 Week Low
- QNCX $0.51
- STTK $0.69
- 52 Week High
- QNCX $2.45
- STTK $4.51
- Technical
- Relative Strength Index (RSI)
- QNCX 50.83
- STTK 47.82
- Support Level
- QNCX $1.75
- STTK $0.73
- Resistance Level
- QNCX $2.05
- STTK $0.92
- Average True Range (ATR)
- QNCX 0.16
- STTK 0.07
- MACD
- QNCX -0.02
- STTK 0.01
- Stochastic Oscillator
- QNCX 9.76
- STTK 56.01
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.